# Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

> clinical trial · VERIFIED · 2026-08-11

Status: ACTIVE_NOT_RECRUITING · Sponsor: Mirati Therapeutics Inc. · Condition: Metastatic Non Small Cell Lung Cancer

- Company: Mirati Therapeutics Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04685135

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.